APRI (Apri), Drug Delivery System, Patient Friendly Drugs San Diego by Apricus Bio

Apricus Bio APRI NexACT

Home Investor Relations Press Releases

Media & Events Press Releases Stock Quotation SEC Filings SEC Filings - XBRL Content Corporate Governance Corporate Presentation Social Media Videos		Press Releases
		Press Releases \| Archives 2013 12AUG Friday, August 12, 2013 ¬12:01 EDT APRICUS BIOSCIENCES REPORTS CORPORATE UPDATE 09AUG Friday, August 9, 2013 ¬12:01 EDT Apricus Biosciences Announces Corporate Update Conference Call 10June Monday, June 10, 2013 ¬01:02 EDT Apricus Biosciences Receives European Approval for Vitaros^® for the Treatment of Erectile Dysfunction 23May Thursday, May 23, 2013 ¬09:16 EDT Apricus Biosciences Prices $17.1 Million Public Offering of Common Stock and Warrants 22May Wednesday, May 22, 2013 ¬16:02 EDT Apricus Biosciences Announces Proposed Public Offering of Common Stock and Warrants 10May Friday, May 10, 2013 ¬02:31 EDT Apricus Biosciences Provides First Quarter 2013 Corporate Update 07May Tuesday, May 07, 2013 ¬14:33 EDT Apricus Biosciences Announces First Quarter 2013 Financial Results Conference Call 07May Tuesday, May 07, 2013 ¬11:00 EDT Apricus Biosciences Announces Poster Presentation of Vitaros^® Data in Men Previously Unresponsive to PDE-5 Inhibitors at American Urological Association Annual Meeting 18Apr Thursday, April 18, 2013 ¬07:01 EDT Apricus Biosciences to Present at 2013 BIO International Convention 01Apr Monday, April 01, 2013 ¬10:02 EDT Apricus Biosciences Announces Sale of Non-Core Assets 18Mar Monday, March 18, 2013 ¬11:16 EDT Apricus Biosciences Provides Corporate Update; Files Annual Report for Quarter and Year Ended December 31, 2012 18Mar Monday, March 18, 2013 ¬11:01 EDT Apricus Biosciences Appoints Richard W. Pascoe as Chief Executive Officer 14Mar Thursday, March 14, 2013 ¬09:01 EDT Apricus Biosciences Announces 2012 Year End Financial Results Conference Call 14Mar Thursday, March 14, 2013 ¬08:46 EDT Apricus Biosciences Announces Ceasing of Financing of French Subsidiaries 13Mar Wednesday, March 13, 2013 ¬16:57 EDT Apricus Biosciences to Present at the 25^th Annual ROTH Conference 07Mar Wednesday, March 7, 2013 ¬08:01 EDT Apricus Biosciences to Present at BIO-Europe Spring 2013 06Feb Wednesday, February 06, 2013 ¬08:01 EDT Apricus Biosciences to Present at the 15^th Annual BIO CEO & Investor Conference 03Jan Thursday, January 03, 2013 ¬07:01 EDT Apricus Biosciences Announces Corporate Goals for 2013 2012 21Nov Wednesday, November 21, 2012 ¬06:31 EDT Apricus Biosciences to Present at the 24^th Annual Piper Jaffray Healthcare Conference 08Nov Thursday, November 08, 2012 ¬09:02 EDT Apricus Biosciences' Executives to Present at Two Upcoming Conferences 07Nov Wednesday, November 07, 2012 ¬07:31 EDT Apricus Biosciences Announces Third Quarter 2012 Financial Results Conference Call 06Nov Tuesday, November 06, 2012 ¬15:37 EDT Apricus Biosciences Announces Management Changes 18Oct Thursday, October 18, 2012 ¬ 12:51 EDT Apricus Biosciences Receives $2.5 Million Payment From Abbott Laboratories for Vitaros^® in Canada 01Oct Monday, October 01, 2012 ¬ 06:01 EDT Apricus Biosciences Announces Intent to File NDS for MycoVa™ in Canada 25Sep Tuesday, September 25, 2012 ¬ 09:59 EDT Apricus Biosciences CEO to Present at Sachs Annual Biotech in Europe Investor Forum 17Sep Thursday, September 17, 2012 ¬ 15:22 EDT Apricus Biosciences Announces Publication in Journal of Pharmaceutics and Drug Delivery Research 13Sep Thursday, September 13, 2012 ¬ 07:03 EDT Apricus Biosciences' Wholly-Owned Subsidiary NexMed (U.S.A.) and Takeda Pharmaceuticals International GmbH Sign Exclusive License Agreement to Market Vitaros^® in the United Kingdom 22Aug Wendersday, August 22, 2012 ¬ 15:02 EDT Apricus Biosciences' CEO to Present at the Stifel Nicolaus 2012 Healthcare Conference 20Aug Monday, August 20, 2012 ¬ 09:43 EDT Apricus Biosciences Announces Podium Presentation of Vitaros^® Clinical Data at 2012 World Meeting on Sexual Medicine 16Aug Thursday, August 16, 2012 ¬ 09:13 EDT Apricus Biosciences Announces Podium Presentation of Femprox^® Phase III Clinical Data at 2012 World Meeting on Sexual Medicine 08Aug Wednesday, August 08, 2012¬ 09:08 EDT Apricus Biosciences Announces Second Quarter 2012 Financial Results Conference Call and Provides Corporate Update 17Jul Tuesday, July 17, 2012¬ 10:06 EDT Apricus Biosciences Issues Statement Regarding Registration of Shares Related to Finesco/Scomedica and PediatRx Transactions 13Jul Friday, July 13, 2012¬ 10:05 EDT Apricus Biosciences Announces Closing of Finesco-Scomedica Transaction 02Jul Monday, July 02, 2012¬ 10:46 EDT Apricus Biosciences' CEO to Present at the JMP Securities Healthcare Conference 20Jun Wednesday, June 20, 2012¬ 16:52 EDT Apricus Biosciences to Own Revenue Generating Leading French Drug Sales & Marketing Company 15Jun Friday, June 15, 2012¬ 09:52 EDT Apricus Biosciences to Present at 2012 BIO International Convention 14Jun Thursday, June 14, 2012¬ 09:37 EDT Apricus Biosciences Submits Response to Swissmedic for Its Vitaros^® Market Application for Erectile Dysfunction 04Jun Monday, June 04, 2012¬ 09:40 EDT Apricus Biosciences Announces Appointment of Paul V. Maier to Its Board of Directors 01Jun Friday, June 01, 2012¬ 08:31 EDT Apricus Biosciences Shareholder Notice: Dr. Irwin Goldstein Presents Phase III Trial Updated Preliminary Findings in Female Sexual Arousal Disorder 29May Tuesday, May 29, 2012¬ 10:36 EDT Apricus Biosciences' CEO to Present at the 2012 Jefferies Global Healthcare Conference 25May Friday, May 25, 2012¬ 13:22 EDT Apricus Biosciences Strengthens Vitaros^® and Nexact^® Patent Estate With Two New Patent Allowances 22May Tuesday, May 22, 2012¬ 10:14 EDT Apricus Biosciences Granted Regulatory Guidance With FDA for MycoVa™ for the Treatment of Onychomycosis 21May Monday, May 21, 2012¬ 09:37 EDT Apricus Biosciences Granted Regulatory Meeting With FDA for Femprox^® for the Treatment of Female Sexual Arousal Disorder 14May Monday, May 14, 2012¬ 09:43 EDT Apricus Biosciences to Present at the 11th Annual JMP Securities Research Conference 11May Friday, May 11, 2012¬ 09:56 EDT Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa™ for the Treatment of Onychomycosis 08May Tuesday, May 08, 2012¬ 09:50 EDT Apricus Biosciences Announces First Quarter 2012 Financial Results Conference Call and Provides Corporate Update 07May Monday, May 07, 2012¬ 10:11 EDT Health Canada Grants Apricus Biosciences Pre-NDS Meeting for Femprox for Female Sexual Arousal Disorder 04May Friday, May 04, 2012¬ 10:06 EDT Apricus Biosciences Announces Poster Presentation of Femprox^® Phase III Clinical Data at American Urological Association Annual Meeting 27apr Friday, April 27, 2012¬ 10:37 EDT Apricus Biosciences Shareholder Notice: Vice President Edward Cox Interviewed on OneMedPlace 26apr Thursday, April 26, 2012¬ 12:02 EDT Apricus Biosciences Receives Notice of Issuance for First Prevonco™ Patent in the United States 22Mar Thursday, March 22, 2012¬ 07:01 EDT Apricus Biosciences Announces Allowance of a NexACT^® Technology-Based Patent in Europe for the Manufacture of DDAIP 14Mar Wednesday, March 14, 2012¬ 10:06 EDT Apricus Biosciences, San Diego Hospice And The Institute For Palliative Medicine Announce A Broad Clinical Research Program Using Nexact^® Technology 09Mar Friday, March 09, 2012¬ 08:01 EDT Apricus Biosciences' CEO to Present at the 24th Annual ROTH OC Growth Stock Conference 08Mar Thursday, March 08, 2012¬ 14:22 EDT Apricus Biosciences Announces 2011 Year End Financial Results Conference Call 08Mar Thursday, March 08, 2012¬ 10:04 EDT Apricus Biosciences, Inc [APRI] to Ring The NASDAQ Stock Market Closing Bell 06Mar Tuesday, March 06, 2012¬ 10:01 EDT APRICUS BIOSCIENCES CEO IS INTERVIEWED ON CDTV.NET 16Feb Thursday, February 16, 2012¬ 10:08 EDT Apricus Biosciences Announces Shareholder Update With New Focus as a Commercially-Driven Specialty Pharmaceutical Company 15Feb Wednesday, February 15, 2012¬ 12:37 EDT Apricus Bioscience's Wholly-Owned Subsidiary NexMed (USA) Signs Exclusive German Collaboration for Vitaros^® for Erectile Dysfunction 09Feb Thursday, February 09, 2012¬ 09:30 EDT Apricus Biosciences Prices $20.0 Million Public Offering Of Common Stock And Warrants 08Feb Wednesday, February 08, 2012¬ 17:22 EDT Apricus Biosciences Announces Proposed Public Offering Of Common Stock And Warrants 03Feb Friday, February 03, 2012¬ 11:27 EDT Apricus Biosciences Announces Acquisition Of Nitromist™ Rights Outside North America 27Jan Friday, January 27, 2012¬ 08:02 EDT Apricus Biosciences Expands Commercial Oncology Offerings Through Agreement With Pediatrx for U.S. Co-Promotion of GRANISOL^® (Granisetron) Oral Solution ... 19Jan Thursday, January 19, 2012¬ 11:02 EDT Apricus Biosciences Retains Argot Partners As Investor Relations Firm 17Jan Tuesday, January 17, 2012¬ 10:08 EDT Apricus Biosciences Announces Allowance of Israeli Patent, Expanding Its Patent Portfolio for the Topical Treatment of Premature Ejaculation 10Jan Tuesday, January 10, 2012¬ 10:56 EDT Apricus Biosciences and Elis Pharma Sign License Agreement for MycoVa™ in the Middle East and the Gulf 09Jan Monday, January 09, 2012¬ 16:16 EDT Apricus Biosciences To Webcast Today’S Presentation At Biotech Showcase™ 2012 In San Francisco 09Jan January, Monday 09, 2012¬ 12:34 EDT Apricus Biosciences and Abbott Sign Exclusive Agreement to Market Vitaros^® (Alprostadil) in Canada 04Jan Wednesday, January 04, 2012¬ 09:55 EDT Apricus Biosciences CEO, Dr. Bassam Damaj, to Present at Biotech Showcase™ 2012 in San Francisco 03Jan Tuesday, January 03, 2012¬ 10:05 EDT Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa™ for Onychomycosis 2011 29Dec Thursday, December 29, 2011¬ 12:35 EDT Apricus Biosciences Completes Acquisition of Topotarget USA, Inc. 16Dec Friday, December 16, 2011¬ 08:06 EDT Apricus Biosciences Launches Commercialization Arm With Definitive Agreement to Acquire Topotarget USA 15Dec Thursday, December 15, 2011¬ 10:05 EDT Apricus Biosciences Announces Oral Presentation of Efficacy and Clinical Safety Data for Vitaros^® and Femprox^® at the African Society for Sexual Medicine Conference 12Dec Monday, December 12, 2011¬ 11:58 EDT Apricus Biosciences' Vitaros^® Podium Presentation Named Best Clinical Presentation 2011 (Male Sexual Disorder) by the Scientific Committee of the Congress ... 08Dec Thursday, December 08, 2011¬ 10:06 EDT Apricus Biosciences Announces Allowance of Additional NexACT^® Patent in Japan 30Nov Wednesday, November 30, 2011¬ 09:48 EDT Apricus Biosciences Announces Podium Presentation of Efficacy and Clinical Safety Data for Vitaros^® at the European Sexual Society Medicine Conference 21Nov Monday, November 21, 2011¬ 09:56 EDT Apricus Biosciences Announces Appointment of Dr. Kleanthis G. Xanthopoulos to Its Board of Directors 15Nov Tuesday, November 15, 2011¬ 09:36 EDT Apricus Biosciences Announces That Its NexACT^® Partner Exodos Life Sciences Has Completed Its pre-IND Meeting With the FDA 14Nov Monday, November 14, 2011¬ 09:52 EDT Femprox^® Phase III Clinical Data From Apricus Biosciences Chosen for a Presentation at the European Society for Sexual Medicine 11Nov Friday, November 11, 2011¬ 13:21 EDT Apricus Biosciences Announces Third Quarter 2011 Financial Results Conference Call 19Oct Wednesday, October 19, 2011¬ 10:36 EDT Apricus Biosciences Announces Issuance of Korean Patent, Expanding Its Patent Portfolio for Its Topical Cream to Treat Premature Ejaculation 13Oct Thursday, October 13, 2011¬ 11:21 EDT Apricus Biosciences Announces New Data Published in the International Journal of Pharmaceutics Confirming Efficiency of NexACT^® Drug Delivery Technology 10Oct Monday, October 10, 2011¬ 10:36 EDT Apricus Biosciences Announces Presentation of Efficacy and Clinical Safety Data for Vitaros^® at Upcoming Industry Conference 06Oct Thursday, October 06, 2011¬ 10:57 EDT Apricus Biosciences to Present Poster of Femprox^® Phase III Clinical Data at Upcoming Industry Conference 04Oct Tuesday, October 04, 2011¬ 10:06 EDT Apricus Biosciences to Present NexACT^® Technology Overview at PODD Drug Delivery Conference 03Oct Monday, October 03, 2011¬ 11:08 EDT Apricus Biosciences Announces Korean Patent Approval for MycoVa™ for Nail Fungus 09Sep Friday, September 09, 2011¬ 14:28 EDT Apricus Biosciences to Provide Overview of Rx and Consumer Healthcare Divisions at the 11^th Annual Biotech in Europe Investor Forum 02Sep Friday, September 02, 2011¬ 10:38 EDT Apricus Biosciences Corrects the Terminology Relating to Its OTC Products 15Aug Thursday, August 15, 2011¬ 10:08 EDT Apricus Biosciences Announces Expansion of Its NexACT^® Patent Portfolio 11Aug Thursday, August 11, 2011¬ 16:35 EDT Apricus Biosciences Announces Second Quarter 2011 Financial Results Conference Call 11Aug Thursday, August 11, 2011¬ 11:39 EDT Apricus Biosciences CEO Interviewed on CEOLIVE.TV 08Aug Monday, August 08, 2011¬ 10:08 EDT Apricus Biosciences To File For Market Authorization To Sell Vitaros^® For Erectile Dysfunction In Latin America 04Aug Thursday, August 04, 2011¬ 13:27 EDT Apricus Biosciences Provides Corporate Mid-Year Update 19Jul Tuesday, July 19, 2011¬ 09:59 EDT Apricus Biosciences Files Marketing Application for Vitaros^® as a Treatment for Erectile Dysfunction in Switzerland 06Jul Wednesday, July 06, 2011¬ 09:05 EDT Apricus Biosciences Sells Bio-Quant CRO Subsidiary to BioTox Sciences 28Jun Tuesday, June 28, 2011¬ 10:52 EDT Apricus Biosciences' Marketing Application for Vitaros^®, for the Treatment of Erectile Dysfunction, is Accepted for Review in Europe 27Jun Monday, June 27, 2011¬ 10:19 EDT Apricus Biosciences Reports Reanalysis of Its U.S. Phase III Trials for MycoVa™ Showing Drug is Effective in Mycological Cure Resulting in Eradication of Nail Fungus 24Jun Friday, June 24, 2011¬ 10:40 EDT Apricus Bio CEO Bassam Damaj to Present at the 2011 Biotechnology Industry Organization (BIO) International Convention 17Jun Friday, June 17, 2011¬ 14:28 EDT Apricus Biosciences' CEO Sees Higher Revenue if Pfizer Viagra^® Litigation is Successful 14Jun Tuesday, June 14, 2011¬ 09:49 EDT Apricus Biosciences Added to Russell Microcap Index 03Jun Friday, June 03, 2011¬ 10:23 EDT Apricus Bio CEO to Present Commercialization Plans for Vitaros^® at Jefferies 2011 Global Healthcare Conference 02Jun Thursday, June 02, 2011¬ 12:06 EDT Apricus Biosciences Appoints Steve Martin as Senior Vice President and Chief Financial Officer 01Jun Wednesday, June 01, 2011¬ 15:10 EDT Apricus Biosciences Produces Videos Describing the Mechanism by Which Its NexACT^® Technology Successfully Delivers Drugs Through the Skin 31May Tuesday, May 31, 2011¬ 9:56 EDT Apricus Biosciences Announces Issuance of Key Patent for RayVa™ for Raynaud's Phenomenon in Israel 26May Thursday, May 26, 2011¬ 13:40 EDT Apricus Biosciences' CEO to Present at Jefferies 2011 Global Healthcare Conference 23May Monday, May 23, 2011¬ 13:43 EDT Apricus Biosciences to Present at the Euro-Biotech Partnering Forum 2011 to Further Its Partnership Efforts 19May Thursday, May 19, 2011¬ 9:50 EDT Apricus Biosciences Will Request Approval of Vitaros^® as a Treatment for Erectile Dysfunction in Switzerland, Based on Guidance From Swiss Regulatory Authorities 18May Wednesday, May 18, 2011¬ 11:05 EDT Apricus Biosciences CEO is Interviewed on CDTV.net 10May Tuesday, May 10, 2011¬ 13:55 EDT Apricus Biosciences Appoints Randy Berholtz as Executive Vice President, General Counsel and Secretary 10May Tuesday, May 10, 2011¬ 9:28 EDT Apricus Biosciences Announces First Quarter 2011 Financial Results Conference Call 03May Tuesday, May 03, 2011¬ 10:22 EDT Apricus Biosciences' Corporate Development Executive Interviewed on Steve Crowley's American Scene 28Apr Thursday, April 28, 2011 ¬ 10:11 EDT Apricus Biosciences Requests Approval of Vitaros^® as a Treatment for Erectile Dysfunction in Europe 27Apr Wednesday, April 27, 2011 ¬ 13:01 EDT Apricus Biosciences to Present at the FSX Investor Conference in San Francisco on April 28, 2011 19Apr Tuesday, April 19, 2011 ¬ 10:35 EDT Apricus Biosciences Building Strong Pipeline and Solid Financials, CEO, Dr. Bassam Damaj, Tells CEO/CFO Magazine 13Apr Wednesday, April 13, 2011 ¬ 15:40 EDT Apricus Biosciences Files for Orphan Drug Designation for RayVa™ 05Apr Tuesday, April 05, 2011 ¬ 12:22 EDT Apricus Biosciences' CEO Interviewed by WallStreetCorner.com 31Mar Thursday, March 31, 2011 ¬ 10:46 EDT Apricus Biosciences Expands Patent Coverage in Mexico for Its Erectile Dysfunction Drug, Vitaros^® 24Mar Thursday, March 24, 2011 ¬ 9:59 EDT Apricus Biosciences Adopts Shareholder Rights Plan 22Mar Tuesday, March 22, 2011 ¬ 9:55 EDT Apricus Biosciences Announces Poster Presentations on Progress of PrevOnco™ in Combination With NexACT^® Technology at the American Association for Cancer Research 2011 Annual Meeting 15Mar Tuesday, March 15, 2011 ¬ 10:01 EDT Apricus Biosciences Announces Formation of Clinical Advisory Board as Part of Its Plans to Further the Clinical Development of Femprox^® 10Mar Thursday, March 10, 2011 ¬ 9:58 EDT Apricus Biosciences to Present at the Bio-Europe Spring 2011 Conference 09Mar Wednesday, March 09, 2011 ¬ 9:31 EDT Apricus Biosciences Announces 2010 Year End Financial Results Conference Call 08Mar Tuesday, March 08, 2011 ¬ 9:59 EDT Apricus Biosciences Announces Removal of Auditor's "Going Concern" Opinion From Its 2010 Form 10-K and Increased Cash Reserves 01Mar Tuesday, March 01, 2011 ¬ 9:16 EDT Apricus Biosciences Announces Expanded European Patent Coverage for MycoVa™ for Nail Fungus 17Feb Thursday, February 17, 2011 ¬ 9:17 EDT Apricus Biosciences and FDA Initiate PrevOnco™ SPA Phase III Clinical Protocol Discussion 14Feb Monday, February 14, 2011 ¬ 10:20 EDT Apricus Biosciences and Neopharm Group Sign Licensing Agreement for Vitaros^® in Israel for up to $4.35 Million, Plus Royalties 10Feb Thursday, February 10, 2011 ¬ 10:14 EDT Apricus Biosciences to Present Review of Commercialization Plans for Vitaros^® and Development of Product Pipeline at BioPartnering North America Conference(TM) 28jan Friday, January 28, 2011 ¬ 11:03 EDT Apricus Biosciences Presents Data on Oral Use of Nexact(R) Technology at the Controlled Release Society Conference 26jan Wednesday, January 26, 2011 ¬ 12:03 EDT Apricus Biosciences' Chief Executive Officer is Interviewed on CDTV.net 19jan Wednesday, January 19, 2011 ¬ 12:03 EDT Apricus Biosciences Reports Additional Analysis Showing That MycoVa™ is as Effective for the Treatment of Nail Fungus as the Current European Standard of Care for Topical Therapy, Loceryl(R) 14jan Friday, January 14, 2011 ¬ 12:03 EDT Apricus Bio Announces Expansion Of Patent Portfolio for Topical Cream to Treat Premature Ejaculation with Issuance Of Japanese Patent 12jan Wednesday, January 12, 2011 ¬ 13:51 EDT Management of Apricus Bio Highlights Corporate Development, Drug Registration and Out-Licensing Progress at Two Biotech Conferences 04jan Tuesday, January 04, 2011 ¬ 10:13 EDT Apricus Biosciences and Elis Pharma Sign License Agreement for Vitaros^® in the Gulf and Part of the Middle East; Apricus Bio to Receive up to $2.1 Million, Plus Royalties 2010 22dec Wednesday, December 22, 2010 ¬ 11:12 EDT Apricus Biosciences and Bracco Sign Licensing Agreement for Vitaros^® in Italy; Apricus Bio to Receive Up to EUR 5.5 Million, Plus Royalties 13dec Monday, December 13, 2010 ¬ 14:00 EDT Apricus Biosciences Announces Upcoming Presentations at the 4^th Annual OneMedForum San Francisco and the Biotech Showcase 2011 06dec Monday, December 06, 2010 ¬ 14:54 EDT Apricus Biosciences Launches Educational Video Series Focused On Its Newly Approved Erectile Dysfunction Drug, Vitaros^® 01dec Wednesday, December 01, 2010 ¬ 15:59 EDT Apricus Biosciences Appoints Manufacturer for Vitaros^® , Its Newly Approved Drug to Treat Erectile Dysfunction in Canada 29nov Monday, November 29, 2010 ¬ 15:12 EDT Apricus Biosciences Announces New NexACT^® Transbuccal Delivery Data Published in the International Journal of Pharmaceutics 22nov Monday, November 22, 2010 ¬ 15:13 EDT Apricus Biosciences Files Phase 3 Registration Protocol for PrevOnco™ for Special Protocol Assessment Consideration by the FDA 19nov Friday, November 19, 2010 ¬ 15:03 EDT Apricus Bio Announces Pre-Clinical Data Showing Significant Improvement in Solubility and Absorption of NexACT^® -Based Small Molecule Drugs Selected from the Biopharmaceutics Classification System 17nov Wednesday, November 17, 2010 ¬ 15:00 EDT Apricus Biosciences' CEO Bassam Damaj, Ph.D., Interviewed by the Financial Network CDTV.net 15nov Monday, November 15, 2010 ¬ 17:21 EDT Apricus Biosciences Receives Canadian Approval for Vitaros^® as First Line Therapy for Erectile Dysfunction 10nov Wednesday, November 10, 2010 ¬ 15:39 EDT Apricus Biosciences Announces 2010 Third Quarter Financial Results Conference Call 09nov Tuesday, November 09, 2010 ¬ 17:40 EDT Apricus Bio's VP of Investor Relations, Edward Cox, Interviewed by Steve Crowley's American Scene 05nov Friday, November 05, 2010 ¬ 16:35 EDT Apricus Bio Apricus Bio Awarded Three Qualifying Therapeutic Discovery Project Grants 25oct Monday, October 25, 2010 ¬ 16:40 EDT Apricus Bio Announces Formation of Clinical Advisory Board 21oct Thursday, October 21, 2010 ¬ 13:01 EDT Apricus Biosciences to Present at the FSX Investor Conference in Phoenix, AZ on October 29, 2010 18oct Monday, October 18, 2010 ¬ 16:30 EDT Apricus Bio Announces First Patent Grant for Femprox^® In Japan 14oct Thursday, October 14, 2010 ¬ 14:00 EDT Apricus Bio Announces IND Filing for Nupen™, Its Proprietary Topical Nupen™ Formulation Containing NexACT^® 13oct Wednesday, October 13, 2010 ¬ 14:02 EDT Apricus Bio Provides Update on Development Activities 11oct Monday, October 11, 2010 ¬ 13:00 EDT Apricus Biosciences To Present At The Precisionir Informed Investors Forum Biotech, Healthcare And Pharma Virtual Conference On October 13 08oct Tuesday, October 08, 2010 ¬ 13:00 EDT Apricus Bio Highlighted in Investment Newsletter 05oct Tuesday, October 05, 2010 ¬ 12:00 EDT Apricus Bio Closes Securities Offering, Raising over $9.3 Million 29sep Wednesday, September 29, 2010 ¬ 12:30 EDT Apricus Bio Announces Pricing of Securities Offering 21sep Tuesday, September 21, 2010 ¬ 19:11 EDT Apricus Bio Receives FDA Guidance on Phase 3 Study Design for RayVa™ Treatment for Raynaud's Syndrome, Secondary to Scleroderma 20sep Monday, September 20, 2010 ¬ 15:00 EDT Apricus Bio Announces Confirmatory Results Qualifying NexACT^® as an Anti-Microbial Preservative 14sep Tuesday, September 14, 2010 ¬ 13:50 EDT Apricus Biosciences Announces Pre-Clinical Results Showing the Ability of the NexACT^® Technology to Enable Rectal Delivery of Biologics 10sep Friday, September 10, 2010 ¬ 20:31 EDT NexMed, Inc. Announces Results of Special Meeting of Stockholders, Including Name Change to Apricus Biosciences 25aug Wednesday, August 25, 2010 ¬ 15:00 EDT NexMed To Present at the Rodman & Renshaw 12^th Annual Healthcare Conference 23aug Monday, August 23, 2010 ¬ 13:00 EDT NexMed Receives Additional Patent Coverage for Israel 26jul Monday, July 26, 2010 ¬ 16:36 EDT Mohamed Hachicha, Ph.D. Joins NexMed, Inc. as Vice President-Research and Development for NexMed, USA 07jul Wednesday, July 07, 2010 ¬ 12:30 EDT NexMed Regains Compliance with NASDAQ Listing Requirements 28jun Monday, June 28, 2010 ¬ 16:09 EDT NexMed to Present PrevOnco™ Data at ILCA Annual Conference 24jun Thursday, June 24, 2010 ¬ 17:20 EDT NexMed Announces First Patent Allowance for Vitaros^® in Japan 23jun Wednesday, June 23, 2010 ¬ 17:54 EDT NexMed Receives Screening Acceptance Letter from Health Canada for Vitaros^® 22jun Tuesday, June, 22 2010 ¬ 13:15 EDT NexMed Announces Appointment of Deirdre Y. Gillespie, M.D. to the Board of Directors 15jun Tuesday, June 15, 2010 ¬ 13:20 EDT NexMed Announces Pre-Clinical Results Showing That Its Proprietary Calcipotriene Betamethasone Psoriasis Formulation is Bioequivalent to Talconex^® 10jun Thursday, June 10, 2010 ¬ 9:07 EDT NexMed Provides Update on Canadian Filing for Vitaros^® 25may Tuesday, May 25, 2010 ¬ 21:00 EDT NexMed Announces Expansion of Senior Business Development Team 17may Monday, May 17, 2010 ¬ 21:11 EDT NexMed to Discuss P2/3 Protocol for NexACT^® -Based Alprostadil Treatment for Raynaud's Syndrome with the FDA 12may Wednesday, May 12, 2010 ¬ 15:19 EDT Nexmed Announces Pre-Clinical Study Showing Vitaros^® Significantly Promotes Wound Healing 10may Monday, May 10, 2010 ¬ 21:19 EDT NexMed Announces Encouraging Pre-Clinical Results Showing the Ability of the NexACT^® Technology to Enhance the Bioavailability of rituximab When Administered Subcutaneously 06may Thursday, May 6, 2010 ¬ 20:45 EDT NexMed Expands Scientific Advisory Board with Appointment of Key Industry Leaders 05may Wednesday, May 5, 2010 ¬ 20:36 EDT NexMed Announces Patent Allowance for NexACT^® in Canada 28Apr Wednesday, April 28, 2010 ¬ 22:47 EDT Pre-Clinical Results Show NexACT^® Technology Significantly Improves Subcutaneous Delivery and Anti-Metastatic Activity of Angstrom's A6 Cancer Compound 27Apr Tuesday, April 27, 2010 ¬ 20:40 EDT NexMed Appoints Dr. Stephen B. Howell, World Renowned Key Opinion Leader in Oncology as Chairman of Its Scientific Advisory Board 26Apr Monday, April 26, 2010 ¬ 14:11:23 EDT NexMed Receives FDA Clearance for PrevOnco™ Phase 2 Study as First-Line Therapy for HCC 22Apr Friday, April 22, 2010 ¬ 00:50 EDT NexMed Files CMC Response with Health Canada for Vitaros^® 13Apr Tuesday, April 13, 2010 ¬ 15:00 EDT NexMed and Ångstrom Pharmaceuticals to Present Data on Å6 Drug at AACR 09Apr Friday, April 09, 2010 ¬ 13:00 EDT NexMed Announces Expansion of Its Bio-Quant Subsidiary Facilities 05Apr Monday, April 05, 2010 ¬ 13:15 EDT NexMed Announces the Expansion of Its Senior Management Team 29Mar Monday, March 29, 2010 ¬ 11:18 EDT Nexmed Files Investigational New Drug Application with Fda for Cancer Drug Candidate 25Mar Thursday, March 25, 2010 ¬ 14:00 EDT NexMed, Inc. to Co-Sponsor Biotalk of Dr. Diego Miralles of Johnson & Johnson at the San Diego Biotechnology Discussion Group 23Mar Tuesday, March 23, 2010 ¬ 17:21 EDT NexMed, Inc. Enters into Distribution Agreement for Japan 17Mar Wednesday, March 17, 2010 ¬ 14:00 EDT NexMed Announces the Ability of Its NexACT^® Technology to Deliver Insulin and Taxol Subcutaneously in a Depot-Like Fashion 17Mar Wednesday, March 17, 2010 ¬ 12:30 EDT NexMed Bolsters Its Cash Reserve with $1.4 Million Infusion from Successful Mortgage Refinancing on Its New Jersey Facility 09Mar Tuesday, March 09, 2010 ¬ 11:06:15 Nexmed To Present At The Roth 22Nd Annual Oc Growth Stock Conference 08Feb Monday, February 08, 2010 ¬ 14:54:29 NexMed Receives over $2.7 Million Cash Infusion 01Feb Monday, February 01, 2010 ¬ 14:54:29 NexMed Granted Request for Continued Listing on NASDAQ 19Jan Tuesday, January 19, 2010 ¬ 14:54:29 Nexmed Updates on Canadian Aproval Process for Vitaros^® 12Jan Tuesday, January 12, 2010 ¬ 14:54:29 NexMed Announces the Ability of the NexACT^® Technology to Deliver Drugs Orally and with Enhanced Bioavailability 08Jan Friday, January 08, 2010 ¬ 10:48:29 NexMed Provides Corporate Update

© 2012 Apricus Biosciences, Inc. All Rights Reserved.

Careers Contact Us Terms of Use Agreement Privacy Policy Safe Harbor Subscribe Sitemap